Squamous cell carcinoma
☆ A cikin sakamakon Stiftung Warentest na 2022 daga Jamus, gamsuwar mabukaci tare da ModelDerm ya ɗan yi ƙasa kaɗan fiye da biyan shawarwarin telemedicine.
Squamous cell carcinoma well differentiated ― Ana lura da keratosis na actinic kusa.
References
Squamous cell carcinoma (SCC) ita ce ta biyu mafi yawan cutar kansar fata a Amurka, bayan basal cell carcinoma. Yawanci yana farawa ne daga raunukan da aka riga aka sani da suna actinic keratosis , kuma yana iya yaduwa zuwa wasu sassan jiki. Babban abin da ke haifar da shi shine fallasa hasken ultraviolet (UV) daga rana, wanda ke taruwa akan lokaci. Jiyya yawanci ya ƙunshi cirewar tiyata, musamman ga SCC a kai da wuya. Maganin radiation wani zaɓi ne ga tsofaffi marasa lafiya ko waɗanda ba za su iya yin tiyata ba. Immunosuppression yana ƙara haɗarin SCC. Ko da yake ba kasafai ba, SCC na iya yaduwa, musamman ma a cikin marasa lafiya da ke da raunin tsarin rigakafi. Dubawa akai-akai da kariyar rana suna da mahimmanci ga waɗanda ke da SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) shine na biyu mafi yawan cutar daji a cikin mutane, kuma adadinsa yana karuwa. Ko da yake CSCC yawanci yana nuna halin rashin lafiya na asibiti, yana iya yaduwa a cikin gida da sauran sassan jiki. Masana kimiyya sun gano takamaiman hanyoyin da ke cikin ci gaban CSCC, wanda ke haifar da sabbin jiyya. Yawan adadin maye gurbi da haɓakar haɗari a cikin marasa lafiya na rigakafi sun haifar da haɓakar rigakafi. Wannan bita na kallon tushen kwayoyin halittar CSCC da sabbin jiyya da ke niyya takamaiman kwayoyin halitta da tsarin rigakafi.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Diagnosis da Magani
#Dermoscopy
#Skin biopsy